We are live on ! Find out more
RAPT

RAPT Therapeutics
RAPT

Delisted

RAPT was delisted on the 2nd of March, 2026.

Back to rankings

98 hedge funds and large institutions have $691M invested in RAPT Therapeutics in 2022 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 38 increasing their positions, 20 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 8

90% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 20

31% more capital invested

Capital invested by funds: $527M → $691M (+$164M)

17% more funds holding

Funds holding: 84 → 98 (+14)

0.1% more ownership

Funds ownership: 12.53% → 12.63% (+0.1%)

0% more funds holding in top 10

Funds holding in top 10: 9 → 9 (0)

Holders
98
Holders Change
+14
Holders Change %
+16.67%
% of All Funds
1.69%
Holding in Top 10
9
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.16%
New
22
Increased
38
Reduced
20
Closed
8
Calls
$19.9M
Puts
–
Net Calls
+$19.9M
Net Calls Change
+$13M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$18.5M
2
O
OrbiMed
New York
+$9.1M
3
WP
Woodline Partners
California
+$8.26M
4
GPP
Great Point Partners
Connecticut
+$7.45M
5
N
Nuveen
North Carolina
+$4.37M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$29.7M
2
KXA
KPCB XV Associates
California
-$15.3M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$12.3M
4
KCM
Kingdon Capital Management
New York
-$8.22M
5
ROTUOC
Regents of the University of California
California
-$7.69M
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
76
Tower Research Capital (TRC)
New York
$168K +$134K +711 +442%
Ensign Peak Advisors
77
Ensign Peak Advisors
Utah
$162K +$45.8K +242 +40%
SG Americas Securities
78
SG Americas Securities
New York
$153K +$150K +794 New
AB
79
Amalgamated Bank
New York
$94K +$946 +5 +1%
AIP
80
Ameritas Investment Partners
Nebraska
$47K +$7.19K +38 +18%
MLICM
81
Metropolitan Life Insurance Company (MetLife)
New York
$38.2K – – –
O
82
OrbiMed
New York
$30.1K +$9.1M +48,084 +44%
Canada Life
83
Canada Life
Manitoba, Canada
$28K – – –
Zurich Cantonal Bank
84
Zurich Cantonal Bank
Switzerland
$19K – – –
Wells Fargo
85
Wells Fargo
California
$19K +$4.73K +25 +35%
PA
86
Parallel Advisors
California
$16K – – –
Russell Investments Group
87
Russell Investments Group
United Kingdom
$13K +$12.9K +68 New
ACM
88
Aquatic Capital Management
Illinois
$12K +$11.9K +63 New
HNWAG
89
High Net Worth Advisory Group
Florida
$12K +$11.9K +63 New
Royal Bank of Canada
90
Royal Bank of Canada
Ontario, Canada
$8K +$4.16K +22 +122%
CUAMC
91
China Universal Asset Management Company
China
$7K +$6.62K +35 New
Osaic Holdings
92
Osaic Holdings
Arizona
$5K – – –
Daiwa Securities Group
93
Daiwa Securities Group
Japan
$2K – – –
US Bancorp
94
US Bancorp
Minnesota
$2K +$1.51K +8 New
Allspring Global Investments
95
Allspring Global Investments
North Carolina
$1K -$21.2K -112 -94%
S
96
SignatureFD
Georgia
$1K – – –
Nisa Investment Advisors
97
Nisa Investment Advisors
Missouri
$1K +$567 +3 New
HM
98
HealthCor Management
New York
– -$3.96M -27,146 Closed
Walleye Capital
99
Walleye Capital
New York
– -$699K -4,790 Closed
E
100
Ergoteles
New York
– -$230K -1,575 Closed
1 2 3
4
5

RAPT Hedge Fund Activity: Q3 2022 in Review

98 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q3 2022, worth a combined $691M — up 31% from $527M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new RAPT positions and 8 closed out — a net gain of 14 holders — while 38 added to existing stakes and 20 trimmed.

The largest buyer was State Street, adding an estimated $18.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $29.7M.

  • 98 institutional investors held RAPT Therapeutics (RAPT) as of Q3 2022, up from 84 in Q2 2022.
  • Funds reported $691M of RAPT Therapeutics stock for Q3 2022, up 31% quarter-over-quarter.
  • 22 funds opened new RAPT Therapeutics positions in Q3 2022 and 8 closed out, a net change of +14 holders.
  • The largest RAPT Therapeutics buyer in Q3 2022 was State Street, an estimated $18.5M added.
  • The largest RAPT Therapeutics seller in Q3 2022 was T. Rowe Price Associates, an estimated $29.7M sold.

Based on aggregated 13F filings for Q3 2022.